You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 273 No. 11, March 15, 1995 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contributions
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Interchangeability of Conjugated Haemophilus influenzae Type b Vaccines in Infants

Edwin L. Anderson, MD; Michael D. Decker, MD, MPH; Janet A. Englund, MD; Kathryn M. Edwards, MD; Porter Anderson, PhD; Pamela Mclnnes, DDS, MSC; Robert B. Belshe, MD

JAMA. 1995;273(11):849-853.


Abstract

Objective.
—To evaluate the safety and immunogenicity of two Haemophilus influenzae type b (Hib) conjugate vaccines when administered in serial combination. These vaccines consisted of Hib capsular polysaccharide polyribosyl-ribitol phosphate (PRP) conjugated to the meningococcal outer membrane protein (OMP) complex (PRP-OMP) and H influenzae oligosaccharide conjugated to a mutant toxin (CRM197) isolated from Corynebacterium diphtheriae (HbOC).

Design.
—Randomized, double-blind, clinical trial evaluating five Hib vaccination regimens.

Setting.
—Vaccine Treatment and Evaluation Units and affiliated private pediatric practices at Saint Louis (Mo) University, Vanderbilt University, Nashville, Tenn, and Baylor College of Medicine, Houston, Tex.

Patients.
—A total of 497 healthy 2-month-old infants scheduled to receive routine immunization.

Intervention.
—Participants received either PRP-OMP or HbOC given as recommended by the manufacturer, PRP-OMP at 2 and 6 months, HbOC at 2 months, then PRP-OMP at 4 and 6 months, or PRP-OMP at 2 months and then HbOC at 4 and 6 months. Unconjugated PRP was given at 15 months to evaluate priming.

Results.
—Geometric mean antibody concentrations differed significantly among the groups following the second and third immunizations of the primary series and following booster immunization with unconjugated PRP. On each occasion, the groups receiving serial combinations of PRP-OMP and HbOC achieved mean antibody concentrations that equalled or exceeded those of the groups receiving a single product. Adverse reactions did not vary by group.

Conclusions.
—The studied sequential combinations of Hib vaccines were safe and at least as immunogenic as either vaccine alone.

(JAMA. 1995;273:849-853)



Author Affiliations

From the Division of Infectious Diseases, Departments of Medicine and Pediatrics (Drs E. L. Anderson and Belshe), Saint Louis (Mo) University School of Medicine; the Departments of Preventive Medicine (Dr Decker), Medicine (Dr Decker), and Pediatrics (Dr Edwards), Vanderbilt University School of Medicine, Nashville, Tenn; the Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Tex (Dr Englund); the Department of Pediatrics, University of Rochester (NY) School of Medicine (Dr P. Anderson); and the Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Disease, Bethesda, Md (Dr Mclnnes). Drs Decker and Edwards have received honoraria from Lederle-Praxis Biologicals for speaking. Dr P. Anderson is a consultant to and stockholder in the manufacturer of one of the vaccines studied, but his role (the antibody assay) was done on coded specimens and he had no contact with the data decoding, data processing, or input on recommendations.


Footnotes

Reprint requests to Saint Louis University Health Sciences Center, Division of Infectious Diseases, 3635 Vista Ave, FDT-8N, PO Box 15250, St Louis, MO 63110 (Dr E. L. Anderson).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Vaccine Interchangeability
Greenberg and Feldman
CLIN PEDIATR 2003;42:93-99.
ABSTRACT  

Active Immunization in the United States: Developments over the Past Decade
Dennehy
Clin. Microbiol. Rev. 2001;14:872-908.
ABSTRACT | FULL TEXT  

Combination Vaccines for Childhood Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP)
Committee on Infectious Diseases, 1998MIHNEAndash1 et al.
Pediatrics 1999;103:1064-1077.
FULL TEXT  

Recommended Childhood Immunization Schedule---United States, January-December 1998
Committee on Infectious Diseases
Pediatrics 1998;101:154-157.
FULL TEXT  

Lot-Release Criteria, Postlicensure Quality Control. and the Haemophilus influenzae Type b Conjugate Vaccines
Egan et al.
JAMA 1995;273:888-889.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.